Publications by authors named "Landt M"
Background: Prosthesis-patient mismatch after transcatheter aortic valve replacement (TAVR) can be measured echocardiographically (measured prosthesis-patient mismatch [PPMm]) or predicted (predicted prosthesis-patient mismatch [PPMp]) using published effective orifice area (EOA) reference values. However, the clinical implications of PPM post-TAVR remain unclear.
Objectives: This study aimed to elucidate the prevalence of PPMm and PPMp post-TAVR and their impact on mortality in a large international cohort.
Introduction: Direct oral anticoagulant (DOAC) dose adjustment is based on age, renal function, and body weight. There is a paucity of data describing the factors associated with the prescription of inappropriate dosage and their impact on clinical outcomes among patients receiving transcatheter aortic valve implantation (TAVI).
Methods: In a single-center study, 432 patients who were on long-term DOAC therapy and underwent TAVI between 2015 and 2022 were included.
Article Synopsis
- Planning noncardiac surgeries after transcatheter aortic valve implantation (TAVI) is complex and this study analyzed the results and outcomes of such surgeries in TAVI patients.
- Out of 1,602 TAVI patients, 104 underwent 148 noncardiac surgeries, with 56.7% being elective and most categorized as intermediate-risk.
- Adverse events occurred in 38.5% of these surgeries, significantly higher in high-risk procedures, indicating a greater risk of complications following high-risk surgeries.
Article Synopsis
- A hybrid strategy combining plug-based and suture-based vascular closure devices (VCDs) was studied to determine the effectiveness of ProGlide/AngioSeal versus ProGlide/FemoSeal after transcatheter aortic valve implantation (TAVI).
- A retrospective study of 608 patients revealed that the ProGlide/AngioSeal group had significantly higher rates of major bleeding and overall complications compared to the ProGlide/FemoSeal group.
- The findings suggest that using ProGlide/FemoSeal may lead to better outcomes within 30 days and that anterior wall calcification at the access site increases the risk of complications.
Background: Recovery processes during residential treatment for eating disorders, especially in patients with a history of maltreatment, are insufficiently understood. This study aimed to explore the temporal relationships among comorbid factors, including depression, anxiety, and self-compassion, with the influence of childhood maltreatment.
Method: Using Dynamic Time Warp (DTW), weekly scores from the Symptom Checklist-5, Eating Disorder Examination, and Self-Compassion Scale were analysed over 12 weeks.
Introduction: The expansion of transcatheter aortic valve implantation (TAVI) to low-risk and younger patients has increased the relevance of the long-term durability of transcatheter heart valves (THV). The present study aims to assess the 10-year durability, hemodynamic performance, and clinical outcomes after TAVI using the CoreValve system.
Methods: An analysis from a prospective registry with predefined clinical and echocardiographic follow-up included 302 patients who underwent TAVI with the CoreValve system between 2007 and 2015.
Article Synopsis
- Some new heart valves called ACURATE neo2 and Evolut PRO were tested to see which one works better and safer for patients getting a special heart procedure.
- The study involved 709 patients, and they checked how well each valve worked and if there were any problems after the procedure.
- Results showed that Neo2 had fewer issues with needing a pacemaker but had more major blood vessel problems, while both valves worked well with no big differences in performance.
Article Synopsis
- The study examined patients with prosthetic valve endocarditis (PVE) after transcatheter aortic valve implantation (TAVI), focusing on those with absent vs. evident echocardiographic signs of infective endocarditis (IE).
- Among 578 patients, 15.1% had no echocardiographic signs, mostly treated via transfemoral access and showing more complications compared to those with evident signs.
- Patients with absent imaging had higher rates of infections from Staphylococcus aureus and enterococci but similar in-hospital and one-year mortality risks, indicating they still represent a high-risk group for IE despite negative imaging.
Objectives: To evaluate the safety and efficacy of lesion preparation using rotational atherectomy (RA) with consecutive cutting balloon angioplasty (Rota-Cut).
Background: Whether the Rota-Cut combination improves stent performance in severely calcified coronary lesions is unknown.
Methods: PREPARE-CALC-COMBO is a single-arm prospective trial in which 110 patients were treated with a Rota-Cut strategy before implantation of sirolimus-eluting stents and compared with patients treated with modified balloon (MB, scoring or cutting) or RA from a historical cohort (the randomized PREPARE-CALC trial).
Article Synopsis
- * A study of 1,332 patients showed that those with an HFA-PEFF score of 5 or higher were generally older and had more health issues like atrial fibrillation and chronic kidney disease, leading to higher cardiovascular mortality and heart failure-related rehospitalization within two years.
- * However, the HFA-PEFF score alone did not significantly predict cardiovascular mortality or rehospitalization, suggesting that additional clinical variables are needed for better risk assessment in this patient population. *
Background: Prosthetic valve regurgitation (PVR) impairs early and mid-term outcomes after transcatheter aortic valve replacement (TAVR). We explored the impact of PVR assessed by transthoracic echocardiography (TTE) and magnetic resonance imaging-regurgitation fraction (MRI-RF) on long-term clinical outcomes.
Methods: PVR was assessed by TTE applying the Valve Academic Research Consortium criteria and MRI-RF (from velocity-encoded phase contrast magnetic resonance sequence) in 424 patients.
Background: Outcomes after transcatheter aortic valve replacement (TAVR) and infectious diseases may vary according to sex.
Methods: This multicentre study aimed to determine the sex differences in clinical characteristics, management, and outcomes of infective endocarditis (IE) after TAVR. A total of 579 patients (217 women, 37.
Scarce data exist on mitral valve (MV) infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). This multicenter study included a total of 579 patients with a diagnosis of definite IE after TAVI from the IE after TAVI International Registry and aimed to evaluate the incidence, characteristics, management, and outcomes of MV-IE after TAVI. A total of 86 patients (14.
View Article and Find Full Text PDFBackground: Direct comparisons of latest-generation balloon-expandable versus self-expanding transcatheter heart valves (THV) are scarce. To compare outcomes after transcatheter aortic valve replacement (TAVR) with SAPIEN 3 Ultra (Ultra) versus Evolut R or Pro (Evolut) THVs.
Methods: 1612 consecutive patients undergoing TAVR with either Ultra (n = 616) or Evolut (n = 996) were included.
Background: Scarce data exist about early infective endocarditis (IE) after trans-catheter aortic valve replacement (TAVR).
Objective: The objective was to evaluate the characteristics, management, and outcomes of very early (VE) IE (≤ 30 days) after TAVR.
Methods: This multicenter study included a total of 579 patients from the Infectious Endocarditis after TAVR International Registry who had the diagnosis of definite IE following TAVR.
Background: The optimal treatment of patients developing infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI) is uncertain.
Objectives: The goal of this study was to investigate the clinical characteristics and outcomes of patients with TAVI-IE treated with cardiac surgery and antibiotics (IE-CS) compared with patients treated with antibiotics alone (IE-AB).
Methods: Crude and inverse probability of treatment weighting analyses were applied for the treatment effect of cardiac surgery vs medical therapy on 1-year all-cause mortality in patients with definite TAVI-IE.
Background: Infective endocarditis (IE) following transcatheter aortic valve replacement (TAVR) has been associated with a dismal prognosis. However, scarce data exist on IE perivalvular extension (PEE) in such patients.
Methods: This multicenter study included 579 patients who had the diagnosis of definite IE at a median of 171 (53-421) days following TAVR.
Background: Staphylococcus aureus (SA) has been extensively studied as causative microorganism of surgical prosthetic-valve infective endocarditis (IE). However, scarce evidence exists on SA IE after transcatheter aortic valve replacement (TAVR).
Methods: Data were obtained from the Infectious Endocarditis After TAVR International Registry, including patients with definite IE after TAVR from 59 centres in 11 countries.
Background: Stroke is one of the most common and potentially disabling complications of infective endocarditis (IE). However, scarce data exist about stroke complicating IE after transcatheter aortic valve replacement (TAVR).
Objectives: The purpose of this study was to determine the incidence, risk factors, clinical characteristics, management, and outcomes of patients with definite IE after TAVR complicated by stroke during index IE hospitalization.
Article Synopsis
- The study observed 552 patients with infective endocarditis (IE) after transcatheter aortic valve replacement (TAVR) to analyze changes over time between pre-2014 and post-2014 cohorts.
- Overall IE rates were stable, but early IE occurrences dropped significantly in the contemporary cohort, with enterococci being the most common bacteria identified.
- In-hospital and one-year mortality rates showed a gradual decline, alongside lower instances of acute kidney injury, although surgical intervention rates remained consistently low across both cohorts.
Objectives: The purpose of this study was to evaluate clinical and echocardiographic outcome data of the CHOICE (Randomized Comparison of Transcatheter Heart Valves in High Risk Patients with Severe Aortic Stenosis: Medtronic CoreValve Versus Edwards SAPIEN XT) trial at 5 years.
Background: The CHOICE trial was designed to compare device performance of a balloon-expandable (BE) transcatheter heart valve (THV) versus a self-expanding (SE) THV.
Methods: The CHOICE trial is an investigator-initiated trial that randomized 241 high-risk patients with severe symptomatic aortic stenosis and an anatomy suitable for treatment with both BE and SE THVs to transfemoral transcatheter aortic valve replacement with either device.
Objectives: The authors sought to estimate possible interference of the Medtronic Evolut R/Pro transcatheter heart valve (THV) frame with coronary access using multislice computed tomography (MSCT) data.
Background: Lower-risk patients undergoing transcatheter aortic valve replacement (TAVR) endure a high cumulative risk of coronary events, but coronary access can be challenging.
Methods: In 101 patients who received an Evolut R/Pro THV, post-TAVR MSCT (performed at a median of 30 days after TAVR) was used to assess possible interference of the elements of the THV frame with coronary access.